Basic Information
| LncRNA/CircRNA Name | lncRNA-ATB |
| Synonyms | LOC109207222 |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | hepatocellular carcinoma |
| ICD-0-3 | C22.0 |
| Methods | qPCR |
| Sample | hepatocarcinoma tissues |
| Expression Pattern | up-regulated |
| Function Description | Expression of lncRNA-ATB was significantly associated with portal vein thrombosis, intrahepatic or extrahepatic metastases, mUICC stage, and the BCLC stage. Large tumors (> 5 cm, HR = 3.851, 95% CI = 1.431-10.364, p = 0.008) and higher lncRNA-ATB expression (HR = 4.158, 95% CI = 1.226-14.107, p = 0.022) were the significant prognostic factors for overall survival. |
| Pubmed ID | 29108251 |
| Year | 2017 |
| Title | Clinical significance of lncRNA-ATB expression in human hepatocellular carcinoma. |
External Links
| Links for lncRNA-ATB | GenBank HGNC NONCODE |
| Links for hepatocellular carcinoma | OMIM COSMIC |